Key Details
Price
$2.40Annual ROE
1697.39%Beta
-0.78Events Calendar
Next earnings date:
Apr 02, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Apr 02, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients
WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year
WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares for inclusion in its Microcap Index. The inclusion became effective at the close of market on Friday, June 28, 2024.
WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index. The inclusion became effective at the close of market on Friday, May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024. A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.
Envoy Medical is a company that provides fully implantable hearing devices for individuals with moderate to severe hearing loss. Their second device, Acclaim, has received Breakthrough Device designation and is set to start clinical trials for FDA approval. Envoy's devices have benefits including no need for external devices, no cleaning necessary, no risk of expensive replacements, and continuous usage around the clock.
White Bear Lake, Minnesota--(Newsfile Corp. - January 30, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing systems, will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ. Brent Lucas, Chief Executive Officer, will be presenting on January 31 & February 1, 2024.
FAQ
- What is the primary business of Envoy Medical?
- What is the ticker symbol for Envoy Medical?
- Does Envoy Medical pay dividends?
- What sector is Envoy Medical in?
- What industry is Envoy Medical in?
- What country is Envoy Medical based in?
- When did Envoy Medical go public?
- Is Envoy Medical in the S&P 500?
- Is Envoy Medical in the NASDAQ 100?
- Is Envoy Medical in the Dow Jones?
- When was Envoy Medical's last earnings report?
- When does Envoy Medical report earnings?
- Should I buy Envoy Medical stock now?